Drug intelligence / Profile preview

miransertib + carboplatin + paclitaxel

Development stage: Unknown
Lead developer: Merck
Modality: Small Molecules
Administration: Oral, Intravenous

Overview

This combination therapy consists of miransertib (ARQ 092), an oral, potent, selective, and allosteric pan-AKT inhibitor, administered alongside the standard chemotherapy agents carboplatin and paclitaxel. Miransertib targets AKT1, AKT2, and AKT3, inhibiting the PI3K/AKT/mTOR pathway, which is frequently dysregulated in various cancers. Carboplatin acts as a DNA alkylating agent, while paclitaxel stabilizes microtubules to inhibit cell division. Developed by ArQule (a Merck subsidiary), this combination was evaluated in Phase 1b clinical trials for advanced solid tumors, specifically focusing on ovarian and endometrial cancers, particularly those harboring PIK3CA, PIK3R1, or AKT1 mutations.

Other names: ARQ 092 + carboplatin + paclitaxel

Targets

AKT2 (Rac-beta serine/threonine-protein kinase)AKT1 (Proto-oncogene serine/threonine-protein kinase Akt1)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on miransertib + carboplatin + paclitaxel.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on miransertib + carboplatin + paclitaxel.

Explore the full profile